# Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.

Study · id `cardio:ct-nct02887183` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02887183](<https://clinicaltrials.gov/study/NCT02887183>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02887183

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 794 participants.

## Technical summary

Registry record NCT02887183. Allocation not applicable; no masking; primary purpose other. Start 2016-10-25 (actual); primary completion 2018-10-22 (actual). Results posted on 2019-12-05.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose other
- Phase: Phase 4
- Enrolled: 794 participants (enrolled count; ClinicalTrials.gov record NCT02887183, source copy `cardio:ctgov-nct02887183-2021-10-07`, retrieved 2026-10-26)
- Started: 2016-10-25 (actual) (ClinicalTrials.gov record NCT02887183, source copy `cardio:ctgov-nct02887183-2021-10-07`, retrieved 2026-10-26)
- Primary completion: 2018-10-22 (actual) (ClinicalTrials.gov record NCT02887183, source copy `cardio:ctgov-nct02887183-2021-10-07`, retrieved 2026-10-26)
- Completion: 2018-10-22 (actual) (ClinicalTrials.gov record NCT02887183, source copy `cardio:ctgov-nct02887183-2021-10-07`, retrieved 2026-10-26)
- Results first posted: 2019-12-05 (ClinicalTrials.gov record NCT02887183, source copy `cardio:ctgov-nct02887183-2021-10-07`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02887183, source copy `cardio:ctgov-nct02887183-2021-10-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02887183-2021-10-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
- Acronym: PROVE-HF
- Condition: Heart Failure
- Intervention (Drug): LCZ696 (sacubitril/valsartan)
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Sacubitril/valsartan (combination) (`cardio:sacubitril-valsartan`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction (`cardio:pubmed-36229089`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study (`cardio:pubmed-36103292`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan (`cardio:pubmed-36599549`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study (`cardio:pubmed-37816446`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 866af7c8ecde0a3e2474582ea59e6c3795eb6f2be957b7542535f3c51aab83f8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
